Close menu




Cancer

Photo credits: pixabay.com

Commented by André Will-Laudien on September 15th, 2022 | 13:35 CEST

Fighting Cancer: BioNTech, Defence Therapeutics, Valneva, MorphoSys - Which biotech stock is ahead in Biden's Moonshot?

  • Biotechnology
  • Cancer
  • vaccine

Since the original launch of the Cancer Moonshot in 2016, the US cancer community has made measurable progress toward three ambitious goals. Namely, accelerating the scientific discovery of cancer, fostering greater collaboration, and improving cancer data sharing. In early 2022, President Biden announced a relaunch of the Cancer Moonshot and named new goals: To cut the cancer death rate in half within 25 years and significantly improve the lives of people with cancer. The initiative is just getting a new lease on life in the United States. Some biotech shares could make significant gains in this environment.

Read

Commented by Mario Hose on August 18th, 2022 | 10:28 CEST

Defence Therapeutics CEO Sébastien Plouffe on the next steps in the battle against cancer

  • Expert
  • DefenceTherapeutics
  • Cancer

A publicly traded biotechnology business called Defence Therapeutics is developing new vaccines and antibody-drug conjugates (ADC) products on its own proprietary platform. The ACCUM technology, which enables precise delivery of vaccine antigens or ADCs in their intact form to target cells, forms the basis of Defence Therapeutics' platform. As a result, catastrophic illnesses like cancer and infectious diseases can be combated with greater efficacy and potency. CEO Sébastien Plouffe gives us background on the company's latest development in the battle against cancer.

Read

Commented by Armin Schulz on August 9th, 2022 | 13:45 CEST

BioNTech, Defence Therapeutics, Valneva - Will biotech stocks continue to rally in the fall?

  • Biotechnology
  • Covid19
  • Cancer

The NASDAQ Biotechnology Index formed a double bottom in mid-June and has since rallied, breaking the downtrend. However, there is still over 32% potential to the past highs. The highs are due in part to the sales from the Corona Crisis, but even though currently the issue is not as present despite higher case numbers, that could change in the fall. The new Protection Against Infection Act provides for mask-wearing and further vaccinations. The profits from these sales are often invested in the development of new therapies, such as cancer research. These areas hold a lot of potential for rising share prices. We take a closer look at three biotech companies.

Read

Commented by Mario Hose on August 2nd, 2022 | 10:57 CEST

Defence Therapeutics VP Research + Development Dr. Moutih Rafei on the next generation oncology-targeting therapies

  • Expert
  • Biotech
  • Cancer
  • DefenceTherapeutics

The publicly traded biotechnology company called Defence Therapeutics is developing new vaccines and ADC products on its own proprietary platform. The Accum technology, which enables precise delivery of vaccine antigens or ADCs in their intact form to target cells, forms the basis of Defence Therapeutics' platform. As a result, catastrophic illnesses like cancer and infectious diseases can be combated with greater efficacy and potency.

Read